Roessler Gernot, Laube Thomas, Brockmann Claudia, Kirschkamp Thomas, Mazinani Babac, Goertz Michael, Koch Christian, Krisch Ingo, Sellhaus Bernd, Trieu Hoc Khiem, Weis Joachim, Bornfeld Norbert, Röthgen Harald, Messner Arthur, Mokwa Wilfried, Walter Peter
Departments of Ophthalmology, RWTH Aachen University, Aachen, Germany.
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):3003-8. doi: 10.1167/iovs.08-2752. Epub 2009 May 6.
Visual sensations in patients with blindness and retinal degenerations may be restored by electrical stimulation of retinal neurons with implantable microelectrode arrays. A prospective trial was initiated to evaluate the safety and efficacy of a wireless intraocular retinal implant (EPIRET3) in six volunteers with blindness and RP.
The implant is a remotely controlled, fully intraocular wireless device consisting of a receiver and a stimulator module. The stimulator is placed on the retinal surface. Data and energy are transmitted via an inductive link from outside the eye to the implant. Surgery included removal of the lens, vitrectomy, and implantation of the EPIRET3 device through a corneal incision. The clinical outcome after implantation and explantation of the device was determined. The implant was removed after 4 weeks, according to the study protocol.
Implantation was successful in all six patients. While the anterior part was fixed with transscleral sutures, the stimulating foil was placed onto the posterior pole and fixed with retinal tacks. The implant was well tolerated, causing temporary moderate postoperative inflammation, whereas the position of the implant remained stable until surgical removal. In all cases explantation of the device was performed successfully. Adverse events were a sterile hypopyon effectively treated with steroids and antibiotics in one case and a retinal break in a second case during explantation requiring silicone oil surgery.
The EPIRET3 system can be successfully implanted and explanted in patients with blindness and RP. The surgical steps are feasible, and the postoperative follow-up disclosed an acceptable range of adverse events.
对于失明和视网膜退行性病变患者,可通过植入式微电极阵列对视网膜神经元进行电刺激来恢复视觉。一项前瞻性试验启动,旨在评估无线眼内视网膜植入物(EPIRET3)在6名失明且患有视网膜色素变性(RP)志愿者中的安全性和有效性。
该植入物是一种遥控的、完全眼内无线设备,由一个接收器和一个刺激器模块组成。刺激器置于视网膜表面。数据和能量通过感应链路从眼外传输至植入物。手术包括晶状体摘除、玻璃体切除术,以及通过角膜切口植入EPIRET3设备。确定了该设备植入和取出后的临床结果。根据研究方案,4周后取出植入物。
6名患者植入均成功。前部通过巩膜外缝线固定,刺激箔片置于后极并用视网膜钉固定。植入物耐受性良好,术后引起短暂的中度炎症,而植入物位置直至手术取出前都保持稳定。所有病例中设备取出均成功。不良事件包括1例无菌性前房积脓,经类固醇和抗生素有效治疗;另1例在取出过程中发生视网膜裂孔,需要硅油手术。
EPIRET3系统能够在失明和RP患者中成功植入和取出。手术步骤可行,术后随访显示不良事件在可接受范围内。